This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Celgene's Abraxane Is Talk of European Cancer Confab

Stocks in this article: CELG CELGZ THLD

VIENNA ( TheStreet) -- Celgene (CELG) hasn't yet announced results from the Abraxane phase III study in pancreatic cancer but the drug generated a lot of positive buzz at this weekend's European Society of Medical Oncology (ESMO) conference.

Cancer consultant guru and blogger Sally Church, in attendance at ESMO, notes oncologists who specialize in pancreatic cancer are typically a dour lot because of the paucity of effective therapies at their disposal. But she was surprised to see these experts in an "excited and feisty mood" Friday because of Abraxane data expected very soon.

On the timing of Celgene announcing results from the Abraxane phase III study, Church writes:

"While it was made abundantly clear by the panel that the final data isn't yet available, all of the KOLs key opinion leaders presenting were at pains to say in their presentations it will be in a "few weeks" or "very soon" so thankfully we won't have long to wait for the press release."

Furthermore, Abraxane sentiment is positive. Again, Church:

"My assumption though, is that the nab-paclitaxel Abraxane is positive since a first cut of the analysis could be available by now, especially if the data will be announced soon. Why else would there be such warm enthusiasm from a well-respected panel?"

Pieter Droppert, Church's colleague and fellow blogger, put together a Storify aggregating Abraxane-related tweets from ESMO 2012 and notes that chatter about the drug overshadowed the presentation of actual pancreatic cancer data from Threshold Pharmaceuticals (THLD).

The best way for investors to play the coming Abraxane data is to buy the Celgene contingent value right (CELGZ) created by Celgene when it acquired Abraxane's original owner Abraxis BioScience in 2010, says hedge fund manager and TheStreet contributor Jim Silverman.

"What I like about the Celgene CVR (CELGZ) is the potential for a nearly $7.50-per-share payout should a phase III study of Abraxane in pancreatic cancer succeed," Silverman wrote in a column last week.

The Celgene CVR rose 10% on Friday to close at 2.83 per share.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs